beclomethasone acetate | 86270-77-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: beclomethasone acetate
• 英文别名: 9α-Chloro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-acetate；[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate
• CAS: 86270-77-1
• 化学式: C₂₄H₃₁ClO₆
• 分子量: 450.96
• InChiKey: LGKOEAPPAOFIQV-QZIXMDIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• MUCOADHESIVE COMPOSITION FOR USE IN THE TREATMENT OF ORAL WOUND
  申请人：Piccolo Federico

  公开号：EP3915568A1

  公开（公告）日：2021-12-01

  The invention relates to a pharmaceutical composition comprising: i. a mucoadhesive polymer; ii. hyaluronic acid or a pharmaceutically acceptable salt thereof, and iii. at least one corticosteroid for use in the treatment of oral wounds, wherein the weight ratio among the components i.: ii.. is in the range from 3:2 to 8:3, preferably post-surgical wounds.

  本发明涉及一种药物组合物，该组合物包含：i.粘液黏附聚合物；ii.透明质酸或其药学上可接受的盐，以及iii.至少一种用于治疗口腔伤口的皮质类固醇，其中各组分i.:ii..之间的重量比在3:2至8:3之间，最好是手术后伤口。
• Dosage form for time-varying patterns of drug delivery
  申请人：——

  公开号：US20030125714A1

  公开（公告）日：2003-07-03

  The present invention provides a multi-release oral drug delivery system that initiates drug release following an initial drug-free release interval, after administration to a subject, and a second drug-free release period before release of another dose of drug. The system has (1) inner compartments enclosed within a semipermeable membrane, and (2) a drug coating on the exterior of the semipermeable membrane surrounded by a microporous membrane, which microporous membrane is permeable to fluid and drug. The drug coating is released after the initial drug-free release interval. An inner compartment drug is released after a second drug-free release interval provided by a drug-free inner compartment.

  本发明提供了一种多重释放口服给药系统，该系统在给受试者用药后的初始无药释放间隔期和释放另一剂量药物前的第二个无药释放期后开始释放药物。该系统有：（1）封闭在半透膜内的内部隔室；（2）在半透膜外部的药物涂层，由微孔膜包围，微孔膜可渗透液体和药物。药物涂层在初始无药物释放间隔期后释放。内室药物在无药物内室提供的第二个无药物释放间隔期后释放。
• Steroidal esters and process for the preparation of steroidal esters
  申请人：PLURICHEMIE ANSTALT

  公开号：EP0072200B1

  公开（公告）日：1985-11-21
• DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE
  申请人：ALZA CORPORATION

  公开号：EP0521074A1

  公开（公告）日：1993-01-07
• DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY
  申请人：ALZA CORPORATION

  公开号：EP0546038B1

  公开（公告）日：1994-07-27